Andaris claims success with Phase I trials of echo agent
This article was originally published in Clinica
UK company Andaris has reported successful completion of Phase I trials of an ultrasound contrast agent. The agent comprises hollow albumin microcapsules measuring 3.0 microns in diameter which are delivered intravenously. The trials showed prolonged systemic Doppler signal enhancement and 2-D opacification of the left and right ventricles and myocardium, according to the company. Andaris, which was set up six months ago, claims that the agent will allow physicians to measure quantitatively cardiac output, ejection fraction and intravascular flow without repeated doses.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.